Cidara Therapeutics (NASDAQ:CDTX – Get Free Report) and Ginkgo Bioworks (NYSE:DNA – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, risk, earnings, dividends, valuation, profitability and analyst recommendations.
Volatility and Risk
Cidara Therapeutics has a beta of 1.13, indicating that its share price is 13% more volatile than the S&P 500. Comparatively, Ginkgo Bioworks has a beta of 1.17, indicating that its share price is 17% more volatile than the S&P 500.
Valuation & Earnings
This table compares Cidara Therapeutics and Ginkgo Bioworks”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Cidara Therapeutics | $63.90 million | 2.52 | -$22.93 million | ($25.52) | -0.90 |
| Ginkgo Bioworks | $217.11 million | 2.50 | -$892.87 million | ($13.08) | -0.72 |
Analyst Recommendations
This is a summary of current ratings and recommmendations for Cidara Therapeutics and Ginkgo Bioworks, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Cidara Therapeutics | 0 | 0 | 5 | 1 | 3.17 |
| Ginkgo Bioworks | 3 | 1 | 1 | 0 | 1.60 |
Cidara Therapeutics presently has a consensus target price of $32.20, suggesting a potential upside of 40.73%. Ginkgo Bioworks has a consensus target price of $4.58, suggesting a potential downside of 51.54%. Given Cidara Therapeutics’ stronger consensus rating and higher possible upside, equities analysts clearly believe Cidara Therapeutics is more favorable than Ginkgo Bioworks.
Insider & Institutional Ownership
35.8% of Cidara Therapeutics shares are held by institutional investors. Comparatively, 78.6% of Ginkgo Bioworks shares are held by institutional investors. 7.6% of Cidara Therapeutics shares are held by insiders. Comparatively, 9.7% of Ginkgo Bioworks shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Profitability
This table compares Cidara Therapeutics and Ginkgo Bioworks’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Cidara Therapeutics | -289.05% | -69.64% | -33.73% |
| Ginkgo Bioworks | -298.78% | -58.54% | -34.24% |
Summary
Cidara Therapeutics beats Ginkgo Bioworks on 8 of the 15 factors compared between the two stocks.
About Cidara Therapeutics
Cidara Therapeutics, Inc., a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that includes CD388, a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. The company was incorporated in 2012 and is based in San Diego, California.
About Ginkgo Bioworks
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
Receive News & Ratings for Cidara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cidara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
